Drug Trial Radar · NCT06902090
Safety, Tolerability and Pharmacokinetics of Meloxicam Nanocrystal Injection in Healthy Subjects
Last checked: Nov 20, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Jul 5, 2023
Primary completion
Jul 25, 2023
Study completion Aug 25, 2023
Sponsor
- Lead sponsor
- Yangtze River Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 30, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Single (participant)
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Primary Objective:To compare the pharmacokinetic profiles between meloxicam nanocrystal injection (strength: 1 mL: 30 mg, Yangtze River Pharmaceutical Group Co., Ltd.) and the originator meloxicam nanocrystal injection (trade name: ANJESO®, strength: 1 mL: 30 mg, Baudax Bio Inc.) in healthy volunteers. Secondary Objective:To observe the safety and tolerability of meloxicam nanocrystal injection and ANJESO® in healthy volunteers.
Conditions
- Pain
Interventions
Meloxicam Nanocrystal Injection(Yangtze River Pharmaceutical Group Co., Ltd.)Drug
IV, 30 mg
Meloxicam Nanocrystal Injection (ANJESO®)Drug
IV, 30 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cmax (Maximum drug plasma concentration)Time frame: up to 96 hours after drug administration
- Tmax (Time to achieve Cmax)Time frame: up to 96 hours after drug administration
- AUC0-t (Total area under the plasma drug concentration-time curve from time of administration to the time of the last quantifiable drug concentration)Time frame: up to 96 hours after drug administration
- AUC0-∞ (Total area under the plasma drug concentration-time curve)Time frame: up to 96 hours after drug administration
- T1/2z (Apparent terminal elimination half-life)Time frame: up to 96 hours after drug administration
- λz (Apparent terminal elimination rate constant)Time frame: up to 96 hours after drug administration
- AUC_%Extrap (The percentage of the portion estimated through extrapolation)Time frame: up to 96 hours after drug administration
- Vz (Volume of distribution during the terminal phase)Time frame: up to 96 hours after drug administration
- CLz (Clearance of the analyte in plasma)Time frame: up to 96 hours after drug administration
- Occurence of adverse eventsTime frame: up to 15 days of each treatment period
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sichuan Provincial People's Hospital
Chengdu, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.